Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 8/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064218 | 1.00 | CCR5 (0.47) | CCR5CYP2D6KCNH2RPS6KA5L3MBTL1 | |
| SCHEMBL4011542 | 0.90 | CCR5 (0.42) | CCR5CYP2D6KCNH2L3MBTL1DYRK1A | |
| SCHEMBL4011538 | 0.90 | CCR5 (0.42) | CCR5CYP2D6KCNH2L3MBTL1DYRK1A | |
| SCHEMBL13141123 | 0.83 | CCR5 (0.57) | CCR5CYP2D6KCNH2RPS6KA5CYP11B2 | |
| SCHEMBL6167230 | 0.81 | CCR5 (0.42) | CCR5CYP2D6KCNH2L3MBTL1CYP11B2 | |
| SCHEMBL6167224 | 0.81 | CCR5 (0.42) | CCR5CYP2D6KCNH2L3MBTL1CYP11B2 | |
| SCHEMBL4138903 | 0.77 | CCR5 (0.58) | CCR5CYP2D6RPS6KA5L3MBTL1DYRK1A | |
| SCHEMBL4019859 | 0.75 | CCR5 (0.54) | CCR5CYP2D6KCNH2 | |
| SCHEMBL4126037 | 0.74 | RPS6KA5 (0.60) | CCR5CYP2D6RPS6KA5L3MBTL1CYP11B2 | |
| SCHEMBL4134368 | 0.73 | CCR5 (0.54) | CCR5CYP2D6L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790740-B2 | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation | PFIZER INC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7579471-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080045563-A1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
| US-7309790-B2 | Chemical compounds | PFIZER INC (US) | 2007-12-18 | — | — | US | disclosed |
| EP-1682545-B1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | PFIZER LTD (GB) | 2007-12-12 | — | — | EP | disclosed |
| US-20070185157-A1 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
| US-7217721-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1682545-A1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | Pfizer Limited (GB) | 2006-07-26 | — | — | EP | disclosed |
| EP-1492789-B1 | TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LTD (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-20050131011-A1 | Chemical compounds | PFIZER, INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050107424-A1 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005033107-A1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | PFIZER LIMITED (GB) | 2005-04-14 | — | — | WO | disclosed |
| US-6855724-B2 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040014742-A1 | Antiinflammatory agents; viricides | PFIZER INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014742-A1 | Antiinflammatory agents; viricides | CCR5, CXCR1, CCR1 | CCR5 1/4885CYP2D6 1795/4885KCNH2 2928/4885 |
| US-20050107424-A1 | Tropane derivatives useful in therapy | CCR5, CXCR4, CX3CR1 | CCR5 1/4885CYP2D6 1468/4885KCNH2 3530/4885 |
| US-20080045563-A1 | IMIDAZOPYRIDINE SUBSTITUTED TROPANE DERIVATIVES WITH CCR5 RECEPTOR ANTAGONIST ACTIVITY FOR THE TREATMENT OF HIV AND INFLAMMATION | CCR5, CCR2, CX3CR1 | CCR5 1/4885CYP2D6 1242/4885KCNH2 2405/4885 |
| US-20070185157-A1 | Tropane derivatives useful in therapy | CCR5, CXCR4, CX3CR1 | CCR5 1/4885CYP2D6 1468/4885KCNH2 3530/4885 |
| US-20050131011-A1 | Chemical compounds | CCR5, CCR2, CX3CR1 | CCR5 1/4885CYP2D6 840/4885KCNH2 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.